ZURAMPIC (lesinurad)
SELF ADMINISTRATION
FDA Approved Indication:
- Indicated in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone
Prior authorization criteria:
- Diagnosis of hyperuricemia associated with gout, AND
- Despite trying and failing first-line agents, patient still has symptomatic hyperuricemia, AND
- Will be used as combination therapy with a xanthine oxidase inhibitor (i.e., allopurinol or Uloric [febuxostat]), AND
- Patient does not have any of the following: severe renal impairment (eCLcr < 45 mL/min), end stage renal disease, is a recipient of a kidney transplant, is on dialysis, or has severe (Child-Pugh class C) hepatic impairment, AND
- Contraindicated for use in tumor lysis syndrome or Lesch-Nyhan syndrome where the rate of uric acid formation is greatly increased
Dosing:
- 200 mg once daily in combination a xanthine oxidase inhibitor
Approval:
- 1 year